Pharma Invest signed a partnership agreement with Yangtze River Pharmaceutical Group (YRPG) on 15 October to advance pharmaceutical cooperation between Algeria and China. The signing ceremony took place at the Ministry of Pharmaceutical Industry in Algiers. This agreement formalizes the collaboration between the two entities as they seek to develop new pharmaceutical projects. Representatives from both organizations attended the event to finalize the terms of the partnership. The deal establishes a framework for the companies to work together on future industrial initiatives within the sector.
The formal commitment marks a significant milestone in the ongoing efforts to bolster the domestic pharmaceutical landscape through international cooperation. By aligning with a major international player, the entities involved aim to create a sustainable pipeline for industrial development. The agreement serves as a foundational document, outlining the roles and expectations for both Pharma Invest and Yangtze River Pharmaceutical Group (YRPG) as they embark on these joint ventures.
Technology Transfer and Production
Pharma Invest and Yangtze River Pharmaceutical Group (YRPG) intend to transfer expertise and modern technology to support the production of pharmaceutical raw materials. This partnership aims to transfer expertise and modern technology for the production of pharmaceutical raw materials. Nassim Kouidri, ministre de l’Industrie pharmaceutique, stated that these efforts "contribuent à orienter l’industrie pharmaceutique nationale vers la production de médicaments innovants et la maîtrise des technologies de pointe pour la fabrication de matières premières à usage pharmaceutique, renforçant ainsi les capacités nationales en la matière et appuyant le processus de concrétisation de la souveraineté sanitaire."
The integration of these technical resources is designed to elevate the local manufacturing standards. By focusing on the production of raw materials, the partnership seeks to reduce external dependencies and foster a more self-reliant pharmaceutical industry. The technology transfer process will be monitored by both parties to ensure that the technical objectives set out in the agreement are met according to the established timelines.
Pharma Invest and the public group Saidal are preparing a separate cooperation agreement. This future arrangement focuses on the manufacturing and distribution of high-value-added medicines. Pharma Invest and the public group Saidal are planning a future cooperation agreement for the manufacturing and distribution of high-value-added medicines. The collaboration between these two entities aims to expand the availability of specialized pharmaceutical products within the domestic market.
This secondary cooperation is expected to complement the broader efforts to modernize the national industrial base. By coordinating with the public group Saidal, Pharma Invest intends to leverage existing domestic infrastructure to facilitate the distribution of these specialized products. The strategic planning for this partnership is currently underway, with both organizations evaluating the necessary logistical requirements to ensure the successful manufacturing and rollout of high-value-added medicines to patients across the country. Through these combined initiatives, the pharmaceutical sector aims to enhance its overall capacity and contribute to the long-term objectives of the industry.